CNS Pharmaceuticals Corp - Aset Bersih saben Siji Saham CNSP

The GURU.Markets terminal provides the book value per share trend, where 12.35 indicates the value of this parameter. CNS Pharmaceuticals (CNSP) is accelerating the market launch of Berubicin through partnerships with Western clinics. Targeted drug development in the US is focused on overcoming the blood-brain barrier. The company is currently in the research stage with no current revenue, relying on the issuance of securities.

CNS Pharmaceuticals Inc (CNSP) - Nilai Akuntansi saben Saham saka 04.07.2022 nganti 28.10.2026

Ringkesan rincian data analitis cnspharma.com (CNSP)

- rega lan prakiraan konsensus rega:

Bagan rega CNS Pharma|CNSP - Target median analis

- data kapitalisasi pasar:

Nilai pasar CNS Pharmaceuticals, Inc.|CNSP - Nilai Wutuh Bisnis

- data kapitalisasi buku:

Nilai Buku saben Saham CNS Pharmaceuticals|CNSP - Aset Bersih Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku cnspharma.com|CNSP - Total Aset Perusahaan

- data utang lan likuiditas:

Utang marang Ekuitas CNS Pharmaceuticals|CNSP - Rasio utang jangka dawa marang modal|Utang jangka cendhak marang modal CNS Pharmaceuticals, Inc.|CNSP - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku CNS Pharmaceuticals, Inc.|CNSP - Utang jangka dawa|Utang jangka cendhak perusahaan CNS Pharmaceuticals

Analisis kabeh metrik perusahaan:CNS Pharma, CNSP

Developing monopoly drugs for the treatment of brain cancer requires colossal capital expenditures, which directly form the net asset base of CNS Pharmaceuticals (CNSP). The book value per share trend reflects the difference between all assets and liabilities per share, allowing investors to assess the real value of CNS Pharmaceuticals (CNSP) without accounting for market speculation and price volatility.

Analisis pesaing CNS Pharmaceuticals

Aset Bersih saben Siji Saham SHPH (Shuttle Pharma)